Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes
Year: 2026
Type: article
Study design: Observational Study
Abstract: Non-small cell lung cancers (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations (UMs) are clinically heterogeneous, and the optimal first-line EGFR tyrosine kinase inhibitor (EGFR-TKI), as well as the role of subsequent immune checkpoint inhibitor (ICI)-based regimens, remains uncertain. We conducted a multicenter retrospective cohort study including patients with advanced or recurrent non-squamous NSCLC harboring UMs who received first-line afatinib or osimertinib between January 2015 and January 2024 at 29 hospitals in Japan, excluding exon 20 insertions and de novo T790M mutations. Inverse probability of treatment weighting adjusted baseline imbalances, and post-EGFR-TKI treatment patterns were evaluated. Among 162 patients (afatinib, n = 95; osimertinib, n = 67), weighted analyses demonstrated no significant differences in time to treatment failure (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.61-1.77) or overall survival (HR, 1.34; 95% CI, 0.73-2.44). Afatinib was associated with higher response rates and more frequent adverse events requiring dose reduction. Subgroup analyses suggested differential treatment effects according to mutation subtype, with osimertinib favoring L861X mutations and afatinib favoring compound mutations. Among 56 patients who received subsequent systemic therapy, clinical outcomes were comparable between ICI plus platinum doublet and platinum doublet alone. These findings indicate that afatinib and osimertinib provide comparable survival outcomes as first-line therapies for NSCLC with UMs, with treatment effects varying by molecular subtype, while subsequent ICI-based regimens may confer limited additional benefit.
Source: Cancer Science
DOI: 10.1111/cas.70400
Authors: Yutaro Nagano, Hiroshi Yokouchi, Ryota Saito, Osamu Honjo, Toshiyuki Sumi, Takayuki Kaburagi, Kenichiro Ito, Yasuyuki Ikezawa, Keiki Yokoo, Hajime Kikuchi, Sayaka Kudo, Masami Yamazoe, Ryota Shigaki, Keita Tagami, Toshiyuki Tenma, Tatsuru Ishikawa, Mamoru Takahashi, Takaaki Sasaki, Hajime Asahina, Shiro Hinotsu, Hirofumi Chiba, Satoshi Oizumi
Institutions: Sapporo Medical University, Sapporo National Hospital, Yamanashi Prefectural Central Hospital, Sapporo Minami Hospital, Hakodate Goryoukaku Hospital, Ibaraki Prefectural Central Hospital, KKR Sapporo Medical Center, Hokkaido University Hospital, Teine Keijinkai Hospital, Obihiro Kosei General Hospital, Kushiro City General Hospital, Hakodate Municipal Hospital, Nayoro City General Hospital, Asahikawa Medical University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,600
Funder: Asahikawa Medical University
OpenAlex ID: W7162948798
